Quantcast
Home > Quotes > HARP

Harpoon Therapeutics, Inc. Common Stock (HARP) Quote & Summary Data

HARP 
$11.92
*  
0.36
2.93%
Get HARP Alerts
*Delayed - data as of Mar. 19, 2019  -  Find a broker to begin trading HARP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
24
Today's High / Low
$ 12.48 / $ 11.872
Share Volume
39,560
50 Day Avg. Daily Volume
N/A
Previous Close
$ 12.28
52 Week High / Low
$ 17.85 / $ 10.53
Market Cap
290,130,774
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
39,560
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $11.92 is 13.20% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 12.48 $ 17.85
 Low: $ 11.872 $ 10.53

Company Description (as filed with the SEC)

We are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using our proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, we are developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Since commencing operations in 2015, we have created four TriTAC product candidates, each of which we expect to be in clinical development by the end of 2020. Our lead TriTAC product candidate, HPN424, is currently in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.  ... More ...  



Risk Grade

Where does HARP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 12.43
Open Date:
Mar. 19, 2019
Close Price:
$ 11.92
Close Date:
Mar. 19, 2019


Consensus Recommendation

Analyst Info